tbuckley/cabot-search huggingface dataset:
Feasibility of vincristine, dactinomycin, and cyclophosphamide (VAC) chemotherapy for adult rhabdomyosarcoma (RMS) with regard to dose intensity (DI).
Authors: Y. Kojima, K. Hashimoto, M. Ando, K. Yonemori, H. Yamamoto, M. Kodaira, M. Yunokawa, C. Shimizu, K. Tamura, N. Katsumata, A. Makimoto, Y. Fujiwara
Journal: Journal of Clinical Oncology (2011)

10083 Background: The prognosis of adult RMS has been considered dismal. The question is raised that VAC chemotherapy may not be administered as per schedule for adult RMS, consequently low DI leads to poor prognosis. Herein, we examined whether the administration of VAC chemotherapy for adult RMS is feasible with regard to the DIs of V and C. Methods: We extracted the data on adult RMS from pts aged greater than or equal to 21 years. Chart review was performed for all identified pts. DI for V or C was calculated according to the following formula: DI (V) = Total dose of V (mg/m2)/[(last date of injection – first date of injection) + 7]/7 or DI (C) = Total dose of C (mg/m2)/[(last date of injection – first date of injection) + 21]/7, respectively. The percentage of relative DI (RDI) was calculated according to the Children's Oncology Group D9803 protocol. Further, we examined the DI in the first 6 cycles of VAC (induction phase) and the DI after the first 6 cycles of VAC (maintenance phase). Results: We identified a total of 27 pts, and a total of 316 cycles of VAC were administered. In the induction phase, the median DIs (mg·m-2·week-1) of V and C were 1.09 and 684.4, respectively. The RDIs for V and C were 81.3% and 93.3%, respectively. In the maintenance phase, the DIs of V and C were 0.77 and 508.0, respectively, while in the maintenance phase, the RDIs for V and C were 51.1% and 69.2%, respectively. The number of pts with RDI more than 80% in the induction phase significantly decreased in the maintenance phase for V (p = 0.0008). Lower RDI of C in the maintenance phase was also showed borderline significance (p = 0.09). In the induction phase (total 168 cycles), the following adverse events were observed: grade 4 neutropenia (77.4%), grade 3/4 anemia (45.8%), grade 4 thrombocytopenia (14.9%), grade 3/4 febrile neutropenia (38.1%), and grade 2 peripheral neuropathy (40.7%). Conclusions: The RDIs of V and C in the maintenance phase were significantly lesser than the corresponding values in the induction phase. Low RDI was mainly attributable to hematologic toxicity and peripheral neuropathy. The maintenance phase chemotherapy for adult RMS should be developed urgently.
Association of Specific Dietary Fats With Mortality
Authors: Martha A. Belury
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Pathogen Reduction Treatment of Whole Blood Inhibits Clot Lysis and Thrombin Generation Is Preserved to 14 Days by Storage At 4°C
Authors: Alejandra G Mora, Heather F Pidcoke, Krystal K Valdez-Delgado, Chriselda G Fedyk, Heather L Reddy, Raymond Goodrich, Andrew P Cap
Journal: Blood (2011)
MRI versus breast-specific gamma imaging (BSGI) in the detection of synchronous breast cancer: A prospective head-to-head trial.
Authors: L. J. Kirstein, J. L. Keto, D. P. Sanchez, T. Fulop, I. Cohen, J. M. Cohen, M. Harshan, S. K. Boolbol
Journal: Journal of Clinical Oncology (2011)

72 Background: Literature suggests that MRI identifies additional mammographically and sonographically occult cancers in 8-10% of newly diagnosed breast cancer patients. We have reported comparable sensitivity of BSGI to MRI in the detection of the known index cancer. We sought to prospectively compare BSGI to MRI in the identification of additional occult malignancies in newly diagnosed breast cancer patients. Methods: Patients with newly diagnosed breast cancer from June 1, 2009 through February 4, 2011 were consented for an IRB approved protocol in which they underwent both breast MRI and BSGI. Each imaging study was read by a dedicated breast radiologist, with one reading all MRI, and another reading all BSGI studies. All subsequent biopsies were performed percutaneously under image guidance and reviewed by dedicated pathologists. The identification of additional occult breast cancers by MRI and BSGI was compared. Results: Eighty-five patients underwent both MRI and BSGI. Twenty-one patients elected to undergo mastectomy without further management of imaging findings and were excluded, leaving 64 eligible patients. No additional lesions were found in 22 patients. Twenty-one patients had benign pathology on biopsied imaging findings. Metastatic axillary lymph nodes, satellite lesions or larger extent of disease was identified in 11 patients. Eleven occult breast cancers were identified in 10 patients (15.6%), 6 on MRI alone (9.4%), 3 on BSGI alone (4.7%), and 2 by both modalities (3.1%). There was no significant difference in the identification of occult cancer between MRI and BSGI (chi-square 0.77, p&gt;0.1; Table). Conclusions: BSGI has previously been shown to be as sensitive as MRI for detecting known invasive and in situ breast carcinoma. This study shows that BSGI is equally sensitive to MRI in the detection of synchronous mammographically and sonographically occult cancers in newly diagnosed breast cancer patients. Further research is needed to identify the false positive rates of BSGI and the effect on surgical management in comparison to MRI. [Table: see text]
A multi-institutional study of 3,794 patients undergoing robotic-assisted laparoscopic radical prostatectomy to determine the surgical learning curve for positive margins and operating time.
Authors: P. Sooriakumaran, M. John, R. Leung, D. Peters, D. Lee, P. Wiklund, A. Tewari
Journal: Journal of Clinical Oncology (2011)

102 Background: The surgical learning curve for robotic assisted laparoscopic radical prostatectomy (RALP) is often cited as being shorter than for other surgical modalities. However, while this appears true with regards to surgical safety, the learning curve for more refined variables like positive surgical margin (PSM) rate and operative time (OT) is not well established. Our objective was to assess the surgical learning curve for RALP in terms of these parameters. Methods: We performed a retrospective cohort study of 3,794 patients who underwent RALP between Jan 2003 and Sep 2009 by three surgeons (DL, PW, AKT) from three centers (UPenn, Karolinska, Cornell). Mean overall PSM rates and mean overall OT were calculated for all three surgeons at intervals of 50 RALPs per surgeon, and learning curves for these means were fit using a loess method. R version 2.71 was used for all statistical analysis. Results: The learning curve for PSM rates for all patients demonstrated improvements that continued with greater surgeon experience, with over 1,600 cases required to get a PSM rate &lt;10%. When only pT3 patients were evaluated, the learning curve started to plateau after 1,000-1,500 cases. Mean OT plateaued after 750 cases although with further surgical experience the OTs started to climb again. Conclusions: The learning curve for RALP is not as short as previously thought, and a large number of cases are needed to get PSM rates and OTs to a minimum. This suggests that RALP should be performed by high volume surgeons in order to optimize patient outcomes. [Table: see text]
Rituximab and Reduced Dose CHOP (R-mini-CHOP) for Patients Over 80 Years with Diffuse Large B-Cell Lymphoma (DLBCL) – Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-7B
Authors: Frederic Peyrade, Fabrice Jardin, Christian Gisselbrecht, Antoine Thyss, Jean François Emile, Sylvie Castaigne, Bertrand Coiffier, Corinne Haioun, Serge Bologna, Olivier Fitoussi, Gerard Lepeu, Christophe Fruchart, Dominique Bordessoule, Michel Blanc, Richard Delarue, Maud Janvier, Bruno Salles, Andre Bosly, Herve Tilly
Journal: Blood (2010)
Can preoperative dynamic contrast-enhanced breast MRI predict extensive occult axillary lymph node metastases in patients with positive sentinel node biopsy?
Authors: C. R. Loiselle, P. R. Eby, J. N. Kim, K. E. Calhoun, K. H. Allison, V. K. Gadi, S. Peacock, B. Storer, D. A. Mankoff, S. C. Partridge, C. D. Lehman
Journal: Journal of Clinical Oncology (2011)

1049 Background: The Katz nomogram is an established clinical-pathologic tool to identify patients with a high likelihood of harboring ≥ 4 occult axillary lymph nodes after a positive sentinel lymph node biopsy. This study examines the ability of preoperative Dynamic Contrast Enhanced MRI (DCE-MRI) to predict which sentinel node positive patients will ultimately have ≥ 4 total positive axillary lymph nodes upon completion axillary dissection and assesses whether DCE-MRI can add predictive value to the Katz nomogram. Methods: Retrospective review of consecutive patients (6/2005 – 12/2009) undergoing sentinel lymph node biopsy was conducted to identify those with invasive breast cancer, clinically negative axillae, preoperative DCE-MRI and positive sentinel node biopsy. Patients who received preoperative chemotherapy or did not undergo axillary dissection were excluded. Clinical and pathologic factors, primary lesion size, and quantitative primary lesion DCE-MRI kinetics, including initial peak enhancement, percent rapid enhancement, and percent washout were collected from clinical records and prospective databases. DCE-MRI parameters with univariate significance (p < 0.05) to predict ≥ 4 axillary nodes were modeled with stepwise regression. Results: 98 patients with 99 positive sentinel lymph node biopsies (one synchronous bilateral case) met study criteria. Stepwise regression identified DCE-MRI volume adjusted peak enhancement and total washout as significant independent predictors of ≥4 metastatic axillary lymph nodes. ROC curves demonstrated an AUC of 0.78 for the Katz nomogram, 0.78 for the DCE-MRI multivariate model, and 0.85 for a combination of the Katz nomogram and DCE-MRI. The combined model was significantly more predictive than the Katz nomogram alone (p = 0.007). Conclusions: DCE-MRI primary lesion kinetics significantly improved the accuracy of the Katz clinical-pathologic nomogram to predict the presence of ≥ 4 axillary node metastases. With validation of these results, DCE-MRI may help predict which sentinel lymph node positive patients have more extensive occult regional adenopathy requiring further therapy.
Patient Satisfaction with Deferasirox (Exjade®, ICL670) an Oral Form of Chelation Therapy Versus Deferoxamine an Infused Chelation Therapy.
Authors: M.D. Cappellini, M. Bejaoui, L. Agaoglu, M.E. Lai, A. Mangiagli, G. Strauss, R. Girot, H. Opitz, L. Abetz, J.F. Baladi, C. Ressayre-Djaffer, J. Ford
Journal: Blood (2005)
Promoting the athlete in every child: physical activity assessment and promotion in healthcare
Authors: Elizabeth A Joy, Felipe Lobelo
Journal: British Journal of Sports Medicine (2016)

The importance of habitual physical activity (PA) on health starts even before a child is born as meeting recommended levels of PA during pregnancy is associated with lower rates of maternal conditions that adversely affect the developing fetus including excessive gestational weight gain, gestational diabetes and pregnancy-induced hypertension.1 Women who are physically active during pregnancy, are also more likely to continue activity postpartum2 and the children of active mothers are more likely to be active themselves;3 thereby elevating the importance of PA promotion during pregnancy and postpartum.

Regular PA is important in each stage of a child's life. Infants and toddlers should be allowed and encouraged to engage in activities that develop essential motor skills.4 Preschool-aged children should participate in activities that begin the process of motor skill development such as kicking and throwing a ball. School-age children spend the majority of their waking hours in school and school-related activities. Active transportation to and from school, recess, quality physical education, sport and after school activities provide numerous opportunities for children and adolescents to achieve the recommended 60 min/day of moderate to vigorous PA.5 ,6 Despite these opportunities, only 27.1% of US high school students surveyed participate in at least 60 min/day of PA on 7 days of the week, and only 29% attend daily physical education.7 By age 15, only 17% of US girls, compared to 33% of boys, report at least 1 hour of moderate-to-vigorous PA daily.8 Multiple sectors of society (eg, school, public health, …
The influence of variant histology on survival outcomes of radical cystectomy for bladder cancer.
Authors: Adrian Stuart Fairey, Eila C. Skinner, Anne Schuckman, Gary Leiskovsky, Jie Cai, Gus Miranda, Siamak Daneshmand
Journal: Journal of Clinical Oncology (2012)

278 Background: The role of variant histology bladder cancer as an independent prognostic factor for survival after radical cystectomy is poorly defined. Our aim was to examine the impact of variant histology on survival. Methods: A retrospective analysis of prospectively collected data from the University of Southern California Bladder Cancer Database was performed. Between 1971 and 2008, 2098 patients underwent radical cystectomy and extended pelvic lymph node dissection for primary bladder cancer. All surgical specimens underwent centralized pathologic review by dedicated genitourinary pathologists. Histologic type was categorized according to the WHO/ISUP 1998 classification as urothelial carcinoma (UC; n=1595), UC + variant (n=380), or non-urothelial carcinoma (Non-UC; n=123). The outcomes were overall survival (OS) and recurrence-free survival (RFS). The Kaplan-Meier method and Cox proportional regression models were used to analyze survival data. Results: The median follow-up duration was 12.8 years (range, 0 to 36.6 years). The predicted 5-year OS (61%, 53%, and 47%, Log rank p=0.005) and RFS (68%, 59%, and 58%, Log rank p=0.001) rates differed between patients with UC, UC + variant, and Non-UC histology. Multivariable analysis showed that Non-UC (but not UC + variant) histology was independently associated with OS (Non-UC versus UC: HR 1.26, 95% CI 1.01 to 1.57, p=0.040; UC + variant versus UC: HR 0.97, 95% CI 0.85 to 1.12, p=0.697) but not RFS (Non-UC versus UC: HR 1.14, 95% CI 0.83 to 1.56, p=0.411; UC + variant versus UC: HR 1.06, 95% CI 0.88 to 1.28, p=0.551). Conclusions: Non-UC histology was independently associated with poorer OS after radical cystectomy for bladder cancer. Clinical trials are needed to determine whether this high risk group will benefit from multimodal therapy.
Clinical Outcomes and Pharmacokinetics of Targeted Intravenous Busulfan in Children Receiving Stem Cell Transplantation for Thalassemia.
Authors: Javi d Gaziev, Luca Spitaleri, Alessia Mozzi, Laurent Nguyen, Christian Puozzo, Michela Perrone, Maria Casella, Paola Polchi, Pietro Sodani, Gabriella Redaelli, Maria Simone, Aldo Montuoro, Marco Marziali, Antonella Isgro, Cristiano Gallucci, Cecilia Alfieri, Katia Paciaroni, Andrea Roveda, Gioia De Angelis, Guido Lucarelli
Journal: Blood (2008)
Complications of Central Venous Catheters in Patients with Hematologic Malignancy: Analysis of Risk Factors.
Authors: Annamaria Nosari, Guido Nador, Andrea de Gasperi, Nichelatti Michele, Anghilieri Michela, Cozzi Paola, Mancini Valentina, Luchesini Camilla, Ricci Francesca, Ciapanna Dennis, Ravelli Erica, Cantoni Silvia, Morra Enrica
Journal: Blood (2004)
Philadelphia Chromosome (Ph’) Secondary Clones in Chronic Myeloid Leukemia (CML) Are Not Indicative of Resistance to IFNa- or Imatinib-Based Treatment Regimens.
Authors: Lorenzo Falchi, Paolo Prontera, Debora Luzi, Viola Festuccia, Rita Emili, Enrico Gottardi, Emilio Donti, Anna Marina Liberati
Journal: Blood (2006)
Identification of SDHA (subunit A of the succinate dehydrogenase) mutations in KIT/PDGFRA WT gastrointestinal stromal tumors (GISTs).
Authors: M. A. Pantaleo, A. Astolfi, V. Indio, P. Paterini, S. Formica, R. Casadio, P. Martelli, A. Maleddu, M. Nannini, A. P. Dei Tos, M. C. Heinrich, D. Santini, F. Catena, C. Ceccarelli, M. Fiorentino, M. di Battista, R. Moore, N. Thiessen, C. Gnocchi, G. Biasco
Journal: Journal of Clinical Oncology (2011)

10045 Background: About 10%-15% of GISTs do not harbour KIT/PDGFRA mutations (wild-type, WT). We analyzed the tumor transcriptome of two sporadic young adults WT GISTs patients using massively parallel sequencing approach in order to identify novel genetic mutations. Methods: Patients were a 28 years-old female (GIST_07) and a 30 years-old male (GIST_10). Primary tumors were in the stomach, multi-centric in GIST_07 and uni-centric in GIST_10, and presented metastases at diagnosis. RNA-Seq paired-end libraries were sequenced on the Illumina GAIIx system using a paired-end strategy at a read length of 75bp. Bioinformatic analysis highlighted 9 candidate genes common to both patients. Mutations in these genes were then filtered with SNP&GO, a tool suited to compute the likelihood of a mutation to be disease-related or not, depending on the protein sequence and its functional annotation. The identified candidate gene was analyzed by Sanger sequencing on tumor (T) and peripheral blood (PB) DNA from GIST_07 and GIST_10 patients, and on additional 8 tumor and 3 PB DNA from 8 sporadic WT GISTs patients. Immunohistochemistry (IHC) was also performed. Results: Only mutations in the sequence of SDHA were identified as disease-related with a high reliability index. GIST_07 tumor DNA was homozygous for an exon 9 p.S384X nonsense mutation; GIST_10 patient showed compound heterozygosity for a germinal exon 2 p.R31X nonsense mutation and a somatic exon 13 p.R589W missense mutation.Heterozygous nonsense mutations were already present in germline DNA in both patients. All mutations lead to functional inactivation of the protein. IHC revealed that both patients showed the down regulation of SDHA. The expanded study showed that 2/10 carried SDHA mutations in the tumor: compound heterozygosity for an exon 9 p.G419R and exon 13 p.E564K mutations in one patient, and a somatic heterozygous exon 5 p.R171C mutation in the other. Conclusions: Recently, SDHB and SDHC mutations were also reported in these patients. This the first study that identifies mutations on SDHA, in 4/10 WT GIST patients. This gene should be evaluated in larger seriesand be added in the sequencing screening of WT GISTs.
Effect of denosumab versus zoledronic acid on health-related quality of life in patients with metastatic breast cancer.
Authors: L. Fallowfield, D. Patrick, J. Body, A. Lipton, K. S. Tonkin, Y. Qian, Q. Jiang, A. H. Braun, R. D. Dansey, K. Chung
Journal: Journal of Clinical Oncology (2011)

272 Background: Patients with breast cancer and bone metastases often experience skeletal-related events (SREs) and pain, which can impact health-related quality of life (HRQoL). Denosumab is superior to zoledronic acid (ZA) in preventing SREs and more effective in delaying moderate or severe pain in patients with advanced breast cancer. We now describe the effect of denosumab or ZA treatment on HRQoL in these patients. Methods: Patients enrolled in this double-blind, double-dummy study were randomized to receive denosumab (120 mg SC) or ZA (4 mg IV) every 4 weeks. Patients completed the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire at baseline (BL), day 8, and each monthly visit to assess overall HRQoL. Higher scores (range 0 to 108) reflect a better HRQoL. Changes in HRQoL were summarized through month 18, when 30% of patients had died or dropped out due to disease progression or withdrawal of consent. Increases or decreases of ≥ 5 points in the FACT-G total score were considered clinically meaningful. Pain was evaluated by the Brief Pain Inventory–Short Form (BPI-SF). HRQoL was assessed in subgroups with no/mild pain or moderate/severe pain at BL. Results: The BL mean (SD) FACT-G score was similar for denosumab (n = 956) 72.7 (16.4) and ZA (n = 952) 73.6 (16.5) groups and increased from BL to month18 for both groups reflecting improved HRQoL. An average of 3.2% more (range 0.9% to 6.8%) denosumab-treated patients than ZA-treated patients experienced a ≥ 5-point increase in HRQoL from months 1 to 18. Fewer denosumab than ZA-treated patients reported a ≥ 5-point decrease in HRQoL (average 2.7% fewer; range 0.6% to 5.8%). Among patients with no/mild pain at BL, an average of 4.1% more (range -0.6% to 9.3%) denosumab-treated patients had a ≥ 5-point increase in FACT-G score from month 4 to 18. In this same subgroup, fewer denosumab-treated patients had a ≥ 5-point decrease in HRQoL over 18 months (average 2.4% fewer; range -4.4% to 6.3%). Similar patterns in FACT-G scores were noted for the subgroup with moderate/severe pain at BL. Conclusions: In patients with advanced breast cancer, a greater proportion treated with denosumab than ZA had a meaningful improvement in HRQoL regardless of BL pain level.
The Use of Purine Analogues During Induction and Consolidation Therapy of Acute Myeloid Leukemia Does Not Increase the Need for More Frequent Transfusions of Red Blood Cell Concentrates, Platelet Concentrates and Fresh Frozen Plasma
Authors: Marek Seweryn, Dariusz Kata, Slawomira Kyrcz-Krzemien
Journal: Blood (2010)